HTB-19 BT-20 人乳癌細(xì)胞, ATCC 細(xì)胞|細(xì)胞系|細(xì)胞株|腫瘤細(xì)胞|細(xì)胞；細(xì)胞庫(kù)管理規(guī)范，提供的細(xì)胞株背景清楚，提供參考文獻(xiàn)和優(yōu)培養(yǎng)條件！

上海復(fù)祥生物科技有限公司是一家專業(yè)從事原代細(xì)胞、細(xì)胞系；菌種；及細(xì)胞因子相關(guān)產(chǎn)品的銷售企業(yè)。公司建有自己的細(xì)胞庫(kù)和菌種庫(kù)。細(xì)胞庫(kù)管理規(guī)范，提供的細(xì)胞株背景清楚，提供參考文獻(xiàn)和最優(yōu)培養(yǎng)條件，公司引進(jìn)ATCC細(xì)胞500余種，ATCC菌種800余種。并和國(guó)內(nèi)各大保藏中心有密切聯(lián)系，細(xì)胞種類齊全，質(zhì)量保證！是生命科學(xué)領(lǐng)域不可缺少的一部分！

HTB-19 BT-20 人乳癌細(xì)胞

ATCC® Number:	HTB-19?	Price:
Designations: BT-20 Depositors: EY Lasfargues Biosafety Level: 1 Shipped: frozen Medium & Serum: See Propagation Growth Properties: adherent Organism: Homo sapiens Morphology: epithelial Source: Organ: mammary gland; breast Disease: carcinoma Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. Isolation: Isolation date: 1958 Applications: BT-20 cells are negative for estrogen receptor, but do express an estrogen receptor mRNA that has deletion of exon 5. This breast tumor line was established by E.Y. Lasfargues and L. Ozzello in 1958 by isolation and cultivation of cells spilling out of the tumor when it was cut in thin slices. Tumorigenic: Yes Reverse Transcript: negative Antigen expression: HLA A1, Bw16 (+/-) DNA Profile (STR): Amelogenin: X CSF1PO: 12 D13S317: 11 D16S539: 11,14 D5S818: 12 D7S820: 10 THO1: 7,9.3 TPOX: 11 vWA: 16,17 Cytogenetic Analysis: Normal chromosomes N3, N4, N9, N13, N14, and X may be absent. The markers der(11)t(11;?)(q25;?) (M1); der(1)t(1;3)(p22?;p13?) (M2); and der(2)t(2;?) (q37;?) (M5) were detected by W.A. Nelson-Rees, et al., Int. J. Cancer 16: 74-85, 1975. Isoenzymes: AK-1, 1-2 ES-D, 1 G6PD, B GLO-I, 1-2 PGM1, 1 PGM3, 1 Age: 74 years Gender: female Ethnicity: Caucasian Comments: The cells express the WNT3 and the WNT7B oncogenes [PubMed: 8168088]. This breast tumor line was established by E.Y. Lasfargues and L. Ozzello in 1958 by isolation and cultivation of cells spilling out of the tumor when it was cut in thin slices. A mycoplasma contaminant was discovered and eliminated early in 1972. Growth of BT-20 cells is inhibited by tumor necrosis factor alpha (TNF alpha). BT-20 cells are negative for estrogen receptor, but do express an estrogen receptor mRNA that has deletion of exon 5. Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°C Subculturing: Protocol: Remove and discard culture medium. Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor. Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes). Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal. Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting. Add appropriate aliquots of the cell suspension to new culture vessels. Incubate cultures at 37°C. Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:4 is recommended Medium Renewal: 2 to 3 times per week Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC inkin?id=30-2003">30-2003 recommended serum:ATCC inkin?id=30-2020">30-2020 References: 21405: Sugarman BJ, et al. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science 230: 943-945, 1985. PubMed: 3933111 22536: Fogh J, et al. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58: 209-214, 1977. PubMed: 833871 23079: Lan MS, et al. Polypeptide core of a human pancreatic tumor mucin antigen. Cancer Res. 50: 2997-3001, 1990. PubMed: 2334903 23110: Castles CG, et al. expression of a constitutively active estrogen receptor variant in the estrogen receptor-negative BT-20 human breast cancer cell line. Cancer Res. 53: 5934-5939, 1993. PubMed: 8261406 23113: Huguet EL, et al. Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast cell lines and normal and disease states of human breast tissue. Cancer Res. 54: 2615-2621, 1994. PubMed:8168088 23212: Lasfargues EY, Ozzello L. Cultivation of human breast carcinomas. J. Natl. Cancer Inst. 21: 1131-1147, 1958. PubMed: 13611537 23226: Pollack MS, et al. HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines. J. Natl. Cancer Inst. 66: 1003-1012, 1981. PubMed: 7017212 32275: Littlewood-Evans AJ, et al. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res. 57: 5386-5390, 1997. PubMed: 9393764 32488: Geiger T, et al. Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice. Anticancer Drug Des. 13: 35-45, 1998. PubMed: 9474241

本頁(yè)產(chǎn)品地址：http://m.mingjiewl.com/sell/show-5889945.html